Anti-Osteocalcin (Glu17), clone 4B6

Detects osteocalcin using this Anti-Osteocalcin (Glu17), clone 4B6, Cat. No. MABS1967, is a mouse monoclonal antibody that detects osteocalcin not carboxylated on Glu17 and has been tested for use in and ELISA and Dot Blot.

Dot Blot Analysis: A 1:250 dilution from a representative lot detected Osteocalcin (Glu17) at a wide range of concentrations (0.8 to 400 ng) (Courtesy of Mathieu Ferron, Ph.D., IRCM, Montreal, Canada).



ELISA Analysis: A representative lot detected Osteocalcin (Glu17) in an indirect ELISA (Courtesy of Mathieu Ferron, Ph.D., IRCM, Montreal, Canada).

ELISA Dot Blot

Clone 4B6 is a mouse monoclonal antibody that detects human osteocalcin only when not carboxylated on the first glutamic acid residue (GLU17). It does not react with carboxylated osteocalcin.

A linear peptide corresponding to 17 amino acids from the central region of the mature human osteocalcin with decarboxylated GLU17 residue (with signal peptide and pro regions cleaved off).

Stable for 1 year at 2-8°C from date of receipt.

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Isotype testing: Identity Confirmation by Isotyping test.

Isotyping Analysis: The identity of this monoclonal antibody is confirmed by isotyping test to be mouse IgG1.

Osteocalcin (UniProt: P02818; also known as Bone Gla protein, BGP, Gamma-carboxyglutamic acid-containing protein) is encoded by the BGLAP gene (Gene ID: 632) in human. Osteocalcin is a member of the osteocalcin/matrix Gla protein family and can constitute 1 to 2% of the total bone protein. It is synthesized by osteoblasts and is a major component of the noncollagenous bone matrix. Osteocalcin is synthesized with a signal peptide (aa 1-23), a propeptide (aa 24-51) that are cleaved to generate active secreted form of osteocalcin (aa 52-100). Osteocalcin displays a high affinity for calcium and binds strongly to apatite. Sixty to ninety percent of de novo synthesized osteocalcin is incorporated into the bone matrix where it binds to hydroxyapatite during matrix mineralization. The remainder of the osteocalcin is released into the circulation where it can be measured as a sensitive marker of bone formation. Osteocalcin found in serum is almost exclusively derived from the bone formation with little or no contribution from the resorption process. A major feature of osteocalcin is the presence of 3 vitamin K-dependent gamma-carboxyglutamic acid (Gla) residues, which are found in the first helical region and interact with the inter-calcium spacing in the HAP lattice. In humans, the percentage of the circulating osteocalcin that is not gamma-carboxylated is used as a biomarker of vitamin K status. Osteocalcin expression in osteoblasts is stimulated by insulin and adiponectin and osteocalcin enhances insulin sensitivity and differentiation in muscle. Serum osteocalcin is elevated in diseases characterized by increased bone turnover such as osteoporosis, hyperparathyroidism and Paget′s disease, and low in conditions associated with low bone turnover such as hypoparathyroidism and growth hormone deficiency. (Ref.: Kanazawa I (2015). World J Diabetes. 6(18): 1345 1354; Gundberg, CM et al. (2012). Adv Nutr 3 (2): 149-157).

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.